Invitro International(IVRO)
USD --+0.00%
Reward34Low
Risk35Moderate
📊75%Data
Revenue down 13% YoY
IVRO
+0.0 · +0.00%
USD · OTCQB
Invitro International | Healthcare
Structurally Challenged
Market Cap:1.82M
ℹ️
Reward Rating
34
Low
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
35
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on IVRO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Invitro International?

develops test kits for non-animal testing applications in the United States and internationally.

IVRO · Verdict

Limited reward · moderate risk

IVRO stands out on balance sheet and volatility, but watch the growth signal.

Based on 88% data coverage

IVRO · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet97/100

    Current ratio 18.57

  • Volatility75/100

    Above average

Watchouts 3

  • Growth13/100

    Rev -10.5% CAGR · earnings -68.5%

  • Cash flow34/100

    -8% free-cash-flow margin

  • Profitability37/100

    0% net margin · 7% ROE

Model-based scoring. For information only — not financial advice.

What is Invitro International?

develops test kits for non-animal testing applications in the United States and internationally. Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivity based on a biomembrane and chemical detection systems. The company is listed on the OTCQB in USA, operating in the Healthcare sector, with a market capitalisation of 1.82M.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue growth is subdued, limiting near-term earnings expansion.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Low (34)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.82M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.16
52 Week Low0.055
Last AnnualSeptember
IPO DateN/A
IncorporatedUSA
Shares Outstanding22M
No. of EmployeesN/A
IndustryDiagnostics & Research
ExchangeOTCQB
Beta-0.824
CurrencyUSD